Kazia Therapeutics : presentation to Biotech Showcase

ASX RELEASE

7 January 2019

KAZIA PRESENTATION TO BIOTECH SHOWCASE

Sydney, 7 January 2019 - Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation which is to be presented by Dr James Garner at Biotech Showcase in San Francisco on Tuesday 8 January 2019.

[ENDS]

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer. Licensed from Genentech in late 2016, GDC-0084 is due to enter a phase II clinical trial early in 2018. Initial data is expected in early calendar 2019, and the study is expected to complete in 2021.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data is expected in the first half of calendar 2018.

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director Mr Bryce Carmine Non-Executive Director

Mr Steven Coffey Non-Executive Director

Dr James Garner Chief Executive Officer, Managing Director

A clinical-stage oncology company with two novel agents in development

Presentation to Biotech Showcase

#BTS19

San Francisco, CA

8 January 2019

ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the "safe- harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking

information contained in this presentation.

1

Kazia has four ongoing clinical trials across two novel programs

GDC-0084

PI3K / mTOR

Inhibitor

Licensed from Genentech in October 2016

Breast Cancer Brain Metastases (BCBM)

(collaboration with Dana-Farber Cancer Institute)

Diffuse Intrinsic Pontine Glioma (DIPG)

(collaboration with St Jude Children's Research Hospital)

Potential future collaborations

Preclinical

Phase I

Phase II

Phase III

Note: All studies performed substantially in US under IND

Kazia has delivered all milestones for 2018, with high-value data read-outs expected in 2019

Cantrixil

Ovarian Cancer

Data read-out from phase 1 study (preliminary efficacy)

*Full publication plans to be determined

✓

✓